Commentary
When the Food and Drug Administration (FDA) approves a pharmaceutical product, it often comes with a stipulation. The producing company must provide complete safety reports once the drug comes into use. This is called after-market surveillance.
It is a mandate often invoked to put fears to rest on the part of people who worry that many drugs on the market are unsafe. The FDA, we are told, is the cop on the beat. The companies have to report back to the government and prove that the drug is safe.
And yet there is a problem, according to a new report out from the Washington Post. Citing an examination of FDA records, the report found “hundreds of postmarket studies listed as delayed.”
In some cases, “the work was delayed by more than a decade, or the manufacturer was still developing a plan for the study. As a result of delays, patients, doctors and others could be left in…




